We have previously demonstrated the therapeutic ability of targeting metabolic vulnerabilities in MM including development of glucose transport (GLUT4) inhibitors and the advantages of combinatorial treatments targeting glucose and glutamine metabolism in MM (51, 141, 142, 174, 175). The gene discussed is SLC2A4; the disease is Miyoshi myopathy.